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Abstract
Chronic biofilm formation by Pseudomonas aeruginosa in cystic fibrosis (CF) lungs is a major 
cause of morbidity and mortality for patients with CF. To gain insights into effectiveness of novel 
anti-infective therapies, the inhibitory effects of fosfomycin, tobramycin, and a 4 : 1 (wt/wt) 
fosfomycin/tobramycin combination (FTI) on Pseudomonas aeruginosa biofilms grown on 
cultured human CF-derived airway cells (CFBE41o-) were investigated. In preformed biofilms 
treated for 16 h with antibiotics, P. aeruginosa CFU per mL were reduced 4 log10 units by both 
FTI and tobramycin at 256 mg L−1, while fosfomycin alone had no effect. Importantly, the FTI 
treatment contained five times less tobramycin than the tobramycin-alone treatment. Inhibition of 
initial biofilm formation was achieved at 64 mg L−1 FTI and 16 mg L−1 tobramycin. Fosfomycin 
(1024 mg L−1) did not inhibit biofilm formation. Cytotoxicity was also determined by measuring 
lactate dehydrogenase (LDH). Intriguingly, sub-inhibitory concentrations of FTI (16 mg L−1) and 
tobramycin (4 mg L−1) and high concentrations of fosfomycin (1024 mg L−1) prevented 
bacterially mediated airway cell toxicity without a corresponding reduction in CFU. Overall, it 
was observed that FTI and tobramycin demonstrated comparable activity on biofilm formation and 
disruption. Decreased administration of tobramycin upon treatment with FTI might lead to a 
decrease in negative side effects of aminoglycosides.
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 Introduction
Pseudomonas aeruginosa is one of the leading causes of early mortality for patients with 
cystic fibrosis (CF) (Gibson et al., 2003). CF is the most common life-threatening genetic 
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disorder among Caucasians, and pathology is caused by mutations in a single gene, encoding 
the cystic fibrosis transmembrane conductance regulator (CFTR) (Gibson et al., 2003). 
CFTR transports chloride across the cellular luminal membrane, and mutation of this protein 
leads to altered chloride transport, thickened mucus secretions in the airways, and decreased 
mucus clearance from the lungs (Boucher, 2004). Pseudomonas aeruginosa exploits these 
defects to establish chronic infection in the thickened airway mucus (Gomez & Prince, 
2007). As a chronic infection, the bacteria exhibit adaptive behaviors that increase their 
tolerance to antibiotics, including the expression of genes leading to biofilm formation.
Biofilm formation is a well-established component of P. aeruginosa infection in CF airways 
(Gomez & Prince, 2007). Biofilms impact several characteristics of the chronic airway 
infection in CF, including increased tolerance to antipseudomonal antibiotics and failure of 
antibiotics to eradicate infections. Biofilms are surface-associated microbial communities 
that can display 10-fold to over 1000-fold increases in antibiotic tolerance compared with 
planktonic (free swimming) bacteria (Mah & O’Toole, 2001; Patel, 2005). In the CF lung, 
this tolerance necessitates increased antibiotic usage for maintenance therapy for chronic P. 
aeruginosa infection, which in turn can lead to greater induced antibiotic resistance. 
Consequently, existing antibiotic therapies are becoming less effective for treating chronic P. 
aeruginosa infections because of observed increases in resistance to the drugs used for 
treatment (Smith et al., 2006; Emerson et al., 2010; Mowat et al., 2011; Plummer & 
Wildman, 2011). Combinations of antibiotics may prove an important strategy for 
suppressing or eliminating chronic airway infection.
Fosfomycin/tobramycin for inhalation (FTI) is a novel antibiotic combination with 
properties that make it an interesting candidate for treating chronic airway infections, such 
as in CF and non-CF bronchiectasis patients (MacLeod et al., 2009). Fosfomycin is a 
phosphonic antibiotic that interferes with bacterial cell wall synthesis across a wide range of 
Gram-positive and Gram-negative bacteria (Shrestha & Tomford, 2001), including anaerobes 
(Altes Gutierrez & Rodriguez Noriega, 1977; Inouye et al., 1989). Tobramycin is an 
aminoglycoside antibiotic that is commonly used to treat Gram-negative infections, and as 
an aerosol, it is commonly used to suppress chronic airway infection in CF (Geller et al., 
2002). It is also demonstrated to have a synergistic benefit when given in combination with 
other antibiotics (MacLeod et al., 2012). Both antibiotics have activity in environments 
where biofilms are present. Fosfomycin’s high treatment success rates for UTIs may be in 
part due to its activity under anaerobic conditions (Inouye et al., 1989), which exist 
throughout the biofilm microenvironment. Tobramycin, the minor component of FTI, is also 
highly active against P. aeruginosa growing planktonically and in biofilms (Ratjen et al., 
2009). Therefore, a combination of fosfomycin and tobramycin formulated for nebulized 
delivery to the airways may be an attractive alternative to treating P. aeruginosa biofilms 
infections. FTI maintains high levels of antibacterial activity in mucin, which is the major 
component of the airway mucus present in elevated amounts in the lungs of chronically 
infected CF patients. In the presence of mucin, fosfomycin enhances the active uptake of 
tobramycin into P. aeruginosa resulting in greater inhibition of protein synthesis, enhanced 
bacterial killing, and ultimately a lower frequency of development of resistance (MacLeod et 
al., 2012).
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In this study, we tested the effects of a novel 4 : 1 (wt/wt) fosfomycin/tobramycin 
combination on P. aeruginosa biofilms. FTI has demonstrated activity against a range of 
Gram-positive and Gram-negative pathogens, including antibiotic-resistant strains (MacLeod 
et al., 2009). However, its activity against bacteria grown in biofilms has not yet been fully 
characterized. To compare the effectiveness of FTI with the component antibiotics, we 
utilized a co-culture model in which P. aeruginosa biofilms were grown on CF airway 
epithelial cells (CFBE41o-) (Anderson et al., 2008; Moreau-Marquis et al., 2010). This 
model system has been previously used to more effectively model the biofilm that forms 
within CF airways (Anderson et al., 2008, 2010; Moreau-Marquis et al., 2008, 2009). We 
tested the effect of antibiotics on these co-culture biofilms. We found that FTI and 
tobramycin administered individually disrupted biofilms to greater extent than other 
antibiotics tested. Intriguingly, treatment with subinhibitory concentrations of FTI, 
fosfomycin, and tobramycin also led to decreased cytotoxicity of the bacteria toward the 
cultured epithelial cells.
 Materials and methods
 Bacterial strains and culture conditions
Pseudomonas aeruginosa strain PAO1 was used for all evaluations (Stover et al., 2000). 
Bacteria were grown in LB broth overnight at 37 °C with shaking prior to experimental 
procedures.
 Antibiotics
Tobramycin sulfate and fosfomycin disodium were obtained from Sigma-Aldrich (St. Louis, 
MO). All antibiotics were diluted from stock solutions into complete tissue culture medium 
to the concentrations indicated.
 Cell culture
For co-culture experiments, we used CFBE41o-cells (CFBE), which are immortalized 
airway epithelial cells homozygous for the common ΔF508 CFTR mutation (Cozens et al., 
1994; Bruscia et al., 2002; Swiatecka-Urban et al., 2005). CFBE cultures were maintained in 
165-cm2 flasks with Feeding Medium [Minimal Essential Medium (MEM) supplemented 
with 10% fetal bovine serum, 2 mM glutamine, 50 U mL−1 penicillin, and 50 μg mL−1 
streptomycin], as previously described (Anderson et al., 2008). Medium was replaced every 
2–3 days.
 Co-culture assays
In preparation for co-culture experiments, 24-well tissue culture plates were seeded with 2 × 
105 CFBE cells in 0.5 mL Feeding Medium per well, as previously described (Anderson et 
al., 2008). Medium was replaced every 2–3 days. Nearly 1–2 days before bacterial 
inoculation, the feeding medium was replaced with MEM without phenol red and 
supplemented with 2 mM glutamine and 10% fetal bovine serum. Plates were considered 
ready to use for experiments 7–10 day after seeding.
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 Biofilm disruption—To assess the ability of antibiotics to disrupt preformed P. 
aeruginosa biofilms, CFBE cells were inoculated with overnight cultures of P. aeruginosa at 
an MOI (multiplicity of infection) of 30 : 1 in Assay Medium (MEM without phenol red, 
supplemented with 2 mM glutamine only), as previously described (Anderson et al., 2008). 
After an hour incubation at 37 °C and 5% CO2, medium was removed and 0.5 mL fresh 
Assay Medium, supplemented with 0.4% arginine, was added, and the co-culture was 
incubated at 37 °C and 5% CO2 for an additional 6 h. This method has been shown to result 
in P. aeruginosa biofilm formation on the cultured epithelial cells within this timeframe 
(Anderson et al., 2008; Moreau-Marquis et al., 2008, 2010). After this incubation, medium 
was replaced with 0.5 mL fresh Assay Medium supplemented with FTI, fosfomycin, or 
tobramycin, and the co-culture was incubated for 16 h at 37 °C and 5% CO2. Biofilm levels 
were assessed by harvesting remaining bacteria, followed by serial dilution and plating on 
LB agar plates for CFU determination. Co-cultures were washed three times with 1 mL PBS 
and then incubated for 10–15 min with 1 mL 0.1% Triton-X 100 to lyse the epithelial cells. 
Supernatants were harvested, vortexed for 3 min, serially diluted, and plated on LB agar 
plates, as previously described (Anderson et al., 2008).
 Biofilm inhibition—Inhibition of biofilm formation was assayed by inoculation of cells 
with P. aeruginosa as above in 0.5 mL Assay Medium, 0.4% arginine, and antibiotics as 
indicated. This assay differed from the biofilm disruption assay described above in that the 
antibiotics were added at the time of inoculation of the monolayer of airway cells by the 
bacteria. The assay was incubated for 16 h at 37 °C and 5% CO2 before biofilm levels were 
assessed as above.
 Cytotoxicity—Epithelial cell cytotoxicity was determined in biofilm disruption and 
inhibition experiments by harvesting 300 μL of supernatant prior to washing the wells with 
PBS. This supernatant was centrifuged at 16 000 g in a microcentrifuge for 2 min, and 50 μL 
was assayed in duplicate for release of lactate dehydrogenase (LDH) using the CytoTox96® 
Non-radioactive Cytotoxicity Assay Kit (G1780, Promega, Madison, WI), according to the 
manufacturer’s instructions (Anderson et al., 2008). 0% cytotoxicity was determined by 
measuring spontaneous release of LDH from CFBE cells (untreated); this value became the 
baseline for the experiment. 100% cytotoxicity was determined by addition of 1% Triton-X 
100 to completely lyse the CFBE cells. To assay the toxicity of antibiotics alone, CFBE 
cells, prepared as above, were incubated with FTI, tobramycin, or fosfomycin for 16 h at 
37 °C and 5% CO2.
 Statistical analysis
Student’s t-tests were performed to reveal statistical differences between treatments. P 
values < 0.05 were considered significant.
 Results
 Disruption of preformed biofilms
To investigate whether FTI, tobramycin, or fosfomycin could disrupt preformed biofilms, P. 
aeruginosa strain PAO1 was co-cultured with airway epithelial cells to form biofilms, as 
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described in previous reports of this model (Anderson et al., 2008; Moreau-Marquis et al., 
2008, 2010). Biofilm levels before treatment with antibiotics reached approximately 3 × 107 
CFU/well. Treatment with FTI and tobramycin appeared to result in dose-dependent effects, 
but none of the three antibiotics completely eradicated P. aeruginosa (Fig. 1). Treatment with 
FTI and tobramycin at 256 mg L−1 resulted in an approximate 10 000-fold (4 log10 CFU per 
well) reduction in P. aeruginosa, while the same concentration of fosfomycin resulted in < 2 
log10 killing (Fig. 1). The 256 mg L−1 FTI (containing 51.2 mg L−1 tobramycin) exerted a 
similar effect on biofilm destruction as 64 mg L−1 tobramycin; both of these treatments 
contain approximately the same amount of tobramycin (Table 1). Likewise, treatment with 
1024 mg L−1 FTI (containing 204.8 mg L−1 tobramycin) and 256 mg L−1 tobramycin 
resulted in similar CFU values (Fig. 1).
 Inhibition of biofilm formation
We further tested whether biofilm formation could be inhibited by FTI, fosfomycin, or 
tobramycin. After 16 h of incubation with antibiotics, complete inhibition of biofilm 
formation was achieved with 64 mg L−1 FTI and 16 mg L−1 tobramycin (Fig. 2). 
Fosfomycin did not inhibit biofilm formation, even at the highest concentration evaluated 
(1024 mg L−1).
 Nonbactericidal effects of antibiotics
The effects of antibiotics on CFBE cytotoxicity are shown in Fig. 3. Treatment with FTI and 
tobramycin (64 mg L−1) resulted in < 10% cytotoxicity to CFBE cells (Fig. 3). Moderate 
cytotoxicity was seen after treatment with 1024 mg L−1 FTI (approximately 12%) and 
tobramycin (approximately 23%). Fosfomycin treatment (1024 mg L−1) resulted in < 10% 
toxicity.
Similar high levels of cytotoxicity (> 70%) were observed for all three drugs in biofilm 
disruption experiments (Fig. 4); 256 mg L−1 FTI and 1024 mg L−1 FTI contain similar 
amounts of tobramycin as the 64 mg L−1 tobramycin and 256 mg L−1 tobramycin 
treatments, respectively (Table 1). We have previously shown that P. aeruginosa biofilms 
exert a high level of cytotoxicity to CFBE cells by 7 h (Anderson et al., 2008, 2010), and 
thus, much of the cytotoxicity in our assays might have occurred before antibiotic addition. 
It is equally likely that extended incubation of biofilms on CFBE cells (23 h total time) 
further enhanced this cytotoxicity.
In biofilm inhibition assays (Fig. 5), < 10% cytotoxicity was observed in CFBE cells treated 
with FTI (16 and 64 mg L−1) or tobramycin (4 and 16 mg L−1). In the case of 16 mg L−1 
tobramycin, this reduced cytotoxicity correlated with complete prevention of biofilm 
formation (Fig. 2). Intriguingly, treatment with 4 mg L−1 tobramycin failed to prevent 
biofilm formation (Fig. 2), but resulted in minimal CFBE cell toxicity (Fig. 5). For 
fosfomycin, < 1 log10 reduction in P. aeruginosa CFU was observed after treatment with 1–
16 mg L−1 (Fig. 2), which correlated with high cytotoxicity (Fig. 5). Higher fosfomycin 
concentrations (1024 mg L−1) also failed to inhibit P. aeruginosa biofilm formation (Fig. 2), 
yet prevented CFBE cell cytotoxicity (Fig. 5). In both biofilm disruption and inhibition 
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experiments, lack of antibiotic treatment resulted in complete bacterial killing of CFBE 
cells, resulting in essentially 100% cytotoxicity (data not shown).
 Discussion
We demonstrated for the first time that a 4 : 1 (wt/wt) fosfomycin/tobramycin combination 
eradicated P. aeruginosa biofilms grown on CF-derived airway cells at concentrations that 
are easily achievable with nebulized delivery (Geller et al., 2002). This finding is relevant 
because P. aeruginosa, persisting in the CF lung as biofilms, displays increased antibiotic 
tolerance compared with planktonic (nonbiofilm) counterparts. FTI is a nebulized antibiotic 
combination that has shown activity toward a wide range of respiratory pathogens including 
methicillin-resistant S. aureus, P. aeruginosa, nontypeable H. influenzae, and Moraxella 
catarhalis (MacLeod et al., 2009). In addition, FTI has a superior frequency of resistance 
profile relative to fosfomycin and tobramycin alone (MacLeod et al., 2009). In this study, we 
compared the activity of FTI, tobramycin, and fosfomycin treatments in eradicating and 
preventing P. aeruginosa biofilm formation on CF-derived airway epithelial cells. We believe 
this biofilm model more closely mimics biofilms established in the airways of patients with 
CF than previous reports using biofilms established directly on plastic. This model also 
informs the relationship of bacteria, antibiotics, and airway epithelial cytotoxicity.
The susceptibility of P. aeruginosa to both antibiotics (and their combination) was 
dramatically less than for previously reported values generated using conventional 
susceptibility testing methods (MacLeod et al., 2009). FTI and tobramycin demonstrated 
comparable activity against preformed biofilms (Fig. 1) as well as the inhibition of new 
biofilms (Fig. 2) on CFBE cells. Fosfomycin exerted very little effect in either type of 
biofilm assay. Studies have shown that P. aeruginosa exhibits a lower metabolic rate in 
biofilms (Xu et al., 1998; Walters et al., 2003; Borriello et al., 2004), which may in part 
explain some of the differences in antimicrobial activity. In addition, fosfomycin acts by 
inhibition of bacterial cell wall biosynthesis and requires actively growing bacteria for 
maximal activity, whereas FTI and tobramycin inhibit protein synthesis and are active 
against slow- and fast-growing bacteria. Combinations consisting of fosfomycin and 
ofloxacin have also shown activity against P. aeruginosa growing in biofilms on an abiotic 
surface (Kumon et al., 1995; Monden et al., 2002). We also noticed that treatment of 
preformed biofilm by 1024 mg L−1 fosfomycin resulted in approximately 106 bacteria 
remaining (Fig. 1), but in biofilm inhibition experiments, this antibiotic treatment led to 
biofilms containing 107 CFU (Fig. 2). While the reasons behind this effect are unclear at this 
time, we speculate that during biofilm inhibition experiments, when P. aeruginosa are 
incubated from the beginning of the experiment with fosfomycin, there might be an adaptive 
response to the presence of the antibiotic. It will be interesting in future experiments to 
explore this phenomenon further.
These studies demonstrate that FTI and tobramycin have comparable activities against P. 
aeruginosa growing in biofilms. This is surprising because on a weight/weight basis, FTI is 
composed of 80% fosfomycin and 20% tobramycin (Table 1). Because tobramycin has a 
much higher molecular weight than fosfomycin (467.5 g mol−1 and 138.1 g mol−1, 
respectively), the molar ratio is approximately 13 : 1, with fosfomycin being the major 
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component. Furthermore, fosfomycin alone showed no inhibition of P. aeruginosa biofilm 
growth (Figs 1 and 2), suggesting that fosfomycin is enhancing the activity of tobramycin. 
These data also strongly suggest that FTI will provide identical levels of bacterial killing of 
P. aeruginosa growing in biofilms as tobramycin, but with the potential for significantly 
reduced development of aminoglycoside ototoxicity and nephrotoxicity (Hammett-Stabler & 
Johns, 1998). In particular, in biofilm disruption experiments, 256 μg mL−1 of both FTI and 
tobramycin resulted in similar levels of biofilm reduction (Fig. 1), but FTI treatment 
achieved this result with much less tobramycin (51.2 μg mL−1). Likewise, in biofilm 
inhibition experiments, similar concentrations of FTI (64 μg mL−1) and tobramycin (16 μg 
mL−1) completely inhibited biofilm formation on CFBE cells (Fig. 2). Although the 
difference in tobramycin content between these inhibition treatments was less dramatic (12.8 
μg mL−1 tobramycin in 64 μg mL−1 FTI), the FTI treatment still contained less tobramycin. 
Future in-depth analyses of different FTI and tobramycin concentrations will further identify 
optimal treatment concentrations for biofilm disruption and biofilm inhibition on CF airway 
cells.
In the CF lung, a hyperinflammatory immune reaction leads to tissue destruction (Gibson et 
al., 2003; Griese et al., 2008; Doring et al., 2011), although bacterially mediated tissue 
destruction also likely occurs. In fact, the P. aeruginosa Type III secretion system (T3SS) 
secretes potent toxins that have been shown to kill a variety of cells, including airway 
epithelial and inflammatory cells (Hauser & Engel, 1999; Sato & Frank, 2004; Yahr & 
Wolfgang, 2006; Anderson et al., 2010). Thus, we felt it is important to measure cytotoxicity 
of the bacteria toward the epithelial cells in co-culture biofilm assays to determine whether 
bacterially mediated toxicity could be decreased or averted with antimicrobial therapy. T3SS 
can be quite active during planktonic existence, but appears to be downregulated in mature 
biofilms (Goodman et al., 2004; Laskowski et al., 2004; Kuchma et al., 2005; Kulasekara et 
al., 2005). The early stages of biofilm formation and P. aeruginosa colonization of the CF 
lung may be crucial for reducing bacterially mediated toxicity during early CF lung infection 
with P. aeruginosa.
Our results suggest that early treatment with FTI, tobramycin, and fosfomycin might help to 
reduce cellular toxicity in the CF lung. We observed that while CFBE cytotoxicity levels 
remained high in the biofilm destruction assays (Fig. 4), addition of FTI or tobramycin could 
prevent toxicity in inhibition experiments (Fig. 5). Even subinhibitory concentrations of FTI, 
tobramycin, and fosfomycin could prevent toxicity in biofilm inhibition experiments (Fig. 
5). In these instances, even though CFBE cells were exposed to a large number of bacteria, 
the cellular toxicity remained quite low. These results suggest that antibiotic treatment could 
influence bacterial gene expression, leading to decreased expression of toxic factors, 
although it is also possible that the antibiotics affected the epithelial cells directly. 
Importantly, antibiotic treatments alone exerted little toxic effect on airway cells (Fig. 3). In 
previous studies, we found that treatment of P. aeruginosa biofilms with tobramycin leads to 
a decrease in bacterial virulence and that this was related, in part, to regulation of T3SS gene 
transcription (Anderson et al., 2008, 2010). There are other examples of antibiotics affecting 
bacterial virulence and inducing host immunomodulatory effects (Wood et al., 2006; 
Anderson et al., 2008; Lopez-Boado & Rubin, 2008). It is possible that treatment of P. 
aeruginosa biofilms by fosfomycin also leads to inhibition of T3SS and other virulence 
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factors. Decreased virulence factor production, in turn, could lead to decreased innate 
immune signaling by airway cells.
The types of analyses herein reported are vital for understanding the complex interaction 
between bacterial growth, biofilm-mediated antibiotic tolerance, inflammatory response, and 
epithelial toxicity. Future studies will further elucidate this intricate host–pathogen 
interaction.
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Fig. 1. 
Destruction of preformed biofilms. Co-culture biofilms were formed for 7 h. These biofilms 
were then treated with the indicated antibiotic concentrations for an additional 16 h. Biofilm 
levels were determined by CFU remaining in the well after treatment. Controls reached 
approximately 3 × 107 CFU per well before treatment. Tob, tobramycin; Fos, fosfomycin; 
Input = bacterial level at the start of antibiotic incubation (see text for details). *P < 0.05, 
compared to Input. Error bars represent standard deviation.
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Fig. 2. 
Inhibition of biofilm formation. Antibiotics were added at the time of inoculation with 
Pseudomonas aeruginosa. Biofilm levels were determined at 16 h after inoculation. Tob, 
tobramycin; Fos, fosfomycin. *P < 0.05, compared to lowest antibiotic concentration. Error 
bars represent standard deviation.
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Fig. 3. 
FTI, tobramycin, and fosfomycin exert little toxic effect on CFBE cells. CFBE cells were 
incubated with FTI, tobramycin (Tob), or fosfomycin (Fos) for 16 h, after which cytotoxicity 
was assessed by measuring LDH release. *P < 0.05, compared to lowest antibiotic 
concentration. Error bars represent standard deviation.
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Fig. 4. 
Cytotoxicity after treatment of preformed biofilms with antibiotics. Conditions correspond 
to those in Fig. 1. Cytotoxicity was determined by measuring LDH release from the 
epithelial cells. 100% cytotoxicity was defined by complete lysis of all epithelial cells by 1% 
Triton-X 100. Tob, tobramycin, Fos, fosfomycin. *P < 0.05, compared to lowest antibiotic 
concentration. Error bars represent standard deviation.
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Fig. 5. 
Cytotoxicity after biofilm inhibition studies. Conditions correspond to those in Fig. 2. 
Cytotoxicity was determined by measuring LDH release from the epithelial cells. Tob, 
tobramycin, Fos, fosfomycin. *P < 0.05, compared to lowest antibiotic concentration. Error 
bars represent standard deviation.
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